Pivagabine
Wikipedia on Answers.com:
Top
Pivagabine
| Pivagabine | |
|---|---|
 |
|
|
4-(2,2-Dimethylpropanoylamino)butanoic acid[citation needed] |
|
| Identifiers | |
| CAS number | 69542-93-4  |
| PubChem | 68888 |
| ChemSpider | 62118 |
| UNII | C53SV0WO4V |
| EC number | 274-038-3 |
| KEGG | D07342 |
| MeSH | N-trimethylacetyl-4-aminobutyric+acid |
| ATC code | N06 |
| Jmol-3D images | Image 1 Image 2 |
|
|
|
|
| Properties | |
| Molecular formula | C9H17NO3 |
| Molar mass | 187.24 g mol−1 |
| Exact mass | 187.120843415 g mol−1 |
| Pharmacology | |
| Routes of administration |
Oral |
| Elimination half-life |
6.4 hours |
| Legal status |
|
| Related compounds | |
| Related alkanoic acids | |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Pivagabine (Tonerg) is an antidepressant and anxiolytic drug which was introduced in Italy in 1997 for the treatment of depressive and maladaptive syndromes. Originally believed to function as a prodrug to GABA,[1] pivagabine is now believed to act via its inhibitory effects on corticotropin-releasing factor (CRF).[2][3][4][5]
See also
References
- ^ Bianchi M, Quadro G, Mourier G, Galzigna L (1983). "Pharmacokinetics and in vitro effects of a 4-aminobutyric acid derivative with anticonvulsant action". Pharmacology 27 (4): 237–40. PMID 6634934.
- ^ Scapagnini U, Matera M (November 1997). "Effects of pivagabine on psychophysical performance and behavioural response in experimental models of stress". Arzneimittel-Forschung 47 (11A): 1310–4. PMID 9450154.
- ^ Esposito G, Luparini MR (November 1997). Pivagabine: a novel psychoactive drug. 47. pp. 1306–9. PMID 9450153.
- ^ Gerra G, Zaimovic A, Giusti F, et al. (July 2001). "Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans". Behavioural Brain Research 122 (1): 93–101. doi:10.1016/S0166-4328(01)00177-2. PMID 11287080. http://linkinghub.elsevier.com/retrieve/pii/S0166-4328(01)00177-2.
- ^ Serra M, Concas A, Mostallino MC, et al. (April 1999). "Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain". Psychoneuroendocrinology 24 (3): 269–84. doi:10.1016/S0306-4530(98)00049-3. PMID 10101733. http://linkinghub.elsevier.com/retrieve/pii/S0306-4530(98)00049-3.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Pivagabine.
Read more